Evidence map›Paper›PMID 36471678›Full record

ReviewJournal of blood medicine2022

Practical Guidance for the Use of Voxelotor in the Management of Sickle Cell Disease.

Christina M Barriteau, Sherif M Badawy

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of blood medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Christina M BarriteauDepartment of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Sherif M BadawyDepartment of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.ORCID 0000-0002-4739-265X
Northwestern University · US

Funding

An mHealth Strategy to Improve Medication Adherence in Adolescents with Sickle Cell DiseaseK23HL150232 · NHLBI · LURIE CHILDREN'S HOSPITAL OF CHICAGO · PI BADAWY, SHERIF MOHAMED · 2020 to 2024
$842k
NHLBI NIH HHS K23 HL150232
6 · The paper itself

Abstract

Sickle cell disease (SCD) is one of the most common inherited blood disorders. Deoxygenated hemoglobin S (HbS) polymerizes and causes anemia and various end organ effects. Voxelotor acts by increasing HbS oxygen affinity, decreasing anemia and hemolysis. Voxelotor is approved for use in individuals with SCD age 4 years and older. Phase 3 trials demonstrated an increase in hemoglobin levels and a decrease in markers of hemolysis; however, data or benefits related to clinical and quality of life outcomes are relatively limited and varied across different studies. This review summarizes the published clinical trials and research studies focused on the use of voxelotor in SCD to provide an evidence-based practical guide for hematology providers on its utilization in clinical settings, including physicians and independent licensed practitioners.

Indexed as

adolescentsadultchildrendisease-modifying therapyhemoglobinopathyoxbrytapediatricsickle cellsickle cell anemiasickle cell diseasevoxelotoryoung adults

Identifiers

PMID36471678
PMCPMC9719266
OpenAlexW4310110453

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.